After years of research and clinical testing, we have developed non-invasive, accurate blood tests for early detection of cancer. By making cancer prevention routine, we enable everyone to take control of their own health. The more people take our breakthrough blood tests, the more lives we can save. Life over cancer.

The Science to Save

With only a saliva sample, we can identify your risk for 25 hereditary cancers. With only a blood sample, we can detect the smallest traces of cancer early - and help in determining your optimal treatment.

Our technology analyzes key indicators unique to cancer. We target multiple cancer biomarkers on our clinically-proven Technology Platforms.


Genetic DNA Mutations can Increase Cancer risk by 20 times Genetic mutations associated with increased cancer risk are passed from parent to offspring. These inherited abnormal genes are in contrast to acquired mutations which occur over time and include environmental factors and lifestyle choices such as smoking or sun exposure. Individuals with certain genetic mutations can have a risk of getting hereditary cancers up to 20 times greater than individuals without these mutations. The CellMax-DNA Genetic Cancer Risk Test identifies 98 genes across 25 hereditary cancers using its proprietary SMSEQ Platform. The test requires only a saliva sample.


Circulating Tumor Cells CTCs are extremely rare cells that drive tumor growth and metastasis. Our patented CMx Platform is clinically proven to detect CTCs in early stage cancer. The CMx Platform uses a biomimetic, lipid-bilayer coated microfluidic chip to capture these rare cells in peripheral blood. This breakthrough has been described in several peer-reviewed journal articles.


Circulating Tumor DNA Often known as a "Liquid Biopsy". Tumors shed small DNA fragments into the bloodstream. This cell‐free DNA is in contrast with circulating tumor cells (CTCs), which are intact tumor cells in the blood stream. Our innovative SMSEQ Platform can detect these rare ctDNA fragments with over >99.999% specificity. Using an optimized form of next-generation sequencing (NGS), the SMSEQ technology isolates and deep sequences thousands of base pairs in order to create an accurate genomic tumor profile.

Select Publications and Abstracts

Analytical validation of a novel circulating tumor DNA detection platform for targeted and immunotherapy selection; AACR Annual Meeting 2018
Pratyush Gupta, Julian Lucas, Alex Atkins, Wen-Sy Tsai, Twinkal Marfatia, Shih-En Chang, Oscar Segurado, Rui Mei

Comparison of rare pathogenic germline variants associated with cancer predisposition syndrome in Taiwan and USA populations; AACR Annual Meeting 2018
Zulfiqar Gulzar, Julian Lucas, Alex Atkins, Stephen Su, Oscar Segurado, Rui Mei

CTC and ctDNA profiling to detect 6 NCCN-guideline recommended classes of alterations for immunotherapy and targeted therapy selection using sample from a single blood draw; AACR Annual Meeting 2018
Huangpin B. Hsieh, Jen-chia Wu, Feng-Ming Lin, Julian Lucas, Alex Atkins, Pratyush Gupta, Hung-Jen Shao, Yen-Lin Chen,Wen-Jie Huang, Chia-Hsun Hsieh, Ruey Kuen Hsieh, Kuo-Wei Chen, Ming-Hong Yen, Mana Javey, Shih-En Chang, Twinkal Marfatia, Drew Watson, Mahul Amin, Ashish Nimgaonkar, Oscar Segurado, Rui Mei

Prospective Clinical Study of Circulating Tumor Cells For Colorectal Cancer Screening; ASCO Gastrointestinal Cancers Symposium 2018
WenSy Tsai, Ashish Nimgaonkar, Oscar Segurado, Ying Chang, Ben Hsieh, Hung-Jen Shao, Jen-Chia Wu, Jr-Ming Lai, Mana Javey, Drew Watson, Rui Mei

Prospective Clinical Study of a Prostate Cancer (PCa) Rule-Out Blood Test for PSA Gray Zone Patients Using a Sensitive Circulating Tumor Cell Assay; ASCO Genitourinary Cancers Symposium 2018
See-Tong Pang, Ying-Hsu Chang, Po-Hung Lin, Ying Chang, Drew Watson, Oscar Segurado, Si-Hong Lu, Jen-chia Wu, Jr-Ming Lai, Hung-Jen Shao, Shih-En Chang, Ben Hsieh, Mana Javey, Rui Mei

CellMax Life

CellMax Life is a leading cancer diagnostics company whose mission is to transform how cancer is diagnosed and managed with globally affordable non-invasive tests for early cancer detection and management. CellMax’s unique expertise in both Circulating Tumor Cell and Next Generation Sequencing of DNA and circulating tumor DNA (ctDNA) has enabled multiple highly effective precision medicine solutions for healthy people as well as patients diagnosed with cancer.

U.S. Headquarters

1271 Oakmead Parkway Sunnyvale, CA 94085 Phone: +1 650-564-3905

Taiwan Office

18F-1 Park Street Nangkang, Taipei City (+886) 0800-555-885 (Taiwan)

© 2018 CellMax Life | All Rights Reserved | Terms and Conditions | Privacy Policy